York life sciences business, OptiBiotix Health, has signed a five-year agreement with Akums Drugs and Pharmaceuticals to exclusively manufacture and supply products containing LPLDL, its cholesterol and blood pressure levels reducing strain, in India.
The company said the agreement is a strategic the answer to extend the opportunities offered by LPLDL into India and Southern Asia.
As per the agreement, Akums, India’s largest contract manufacturing organisation, will manufacture and give products containing OptiBiotix’s LPLDL throughout India to optimize the financial return equally for parties.
In return for exclusivity, Akums provides undisclosed and in-kind contributions all of which will explore the chance to utilise LPLDL with OptiBiotix for biotherapeutics in India.
OptiBiotix CEO Stephen O’Hara said: “This agreement is often a strategic step to add manufacturing on the logistics within the Asian probiotic supplement and pharmaceutical market and extends the commercial reach of OptiBiotix’s LPLDL strain into Southern Asia.
“This allows OptiBiotix to present multiple product strategies to consumer health insurance pharmaceutical companies while in the region.
“This agreement is the one other part in a method intended to build multiple revenue streams from ingredient sales, white label and own label branded consumer and pharmaceutical products, across multiple channels, with leading industry partners from around the world.”